Bempedoic Acid Therapy for Polycystic Kidney Disease | MicrobiomeTrials← Back to trialsNCT07282821
Bempedoic Acid Therapy for Polycystic Kidney Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-21Est. Completion: 2029-09-30
Enrollment target: 120 participants Locations- University of Maryland, Baltimore, Baltimore, Maryland, United States
- Tufts University Medical Center, Boston, Massachusetts, United States
- University of Vermont Medical Center, Burlington, Vermont, United States
Other microbiome trials you might be interested in
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This is a Phase 1, First-in-Human study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (P…
Southport, AustraliaEst. completion Nov 2028
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene varian…
Alabaster, United StatesEst. completion Dec 31, 2026